This systematic review aims to assess the effectiveness of AI-Driven Decision Support Systems in improving glycemic control, measured by Time in Range (TIR) and HbA1c levels, in patients with diabetes. Included studies were randomized controlled tria...
Since the discovery of the life-saving hormone insulin in 1921 by Dr. Frederick Banting in 1921, there have been many critical discoveries and technical breakthroughs that have enabled people living with type 1 diabetes (T1D) to live longer, healthie...
BACKGROUND: Managing blood glucose levels in Type 1 Diabetes Mellitus (T1DM) is essential to prevent complications. Traditional insulin delivery methods often require significant patient involvement, limiting automation. Reinforcement Learning (RL)-b...
Hypoglycemia is a serious complication in individuals with type 2 diabetes mellitus. Identifying who is most at risk remains challenging due to the non-linear relationships between hypoglycemia and its associated risk factors. The objective of this s...
IMPORTANCE: Type 2 diabetes (T2D) is one of the most prevalent chronic diseases in the world. Insulin titration for glycemic control in T2D is crucial but limited by the lack of personalized and real-time tools.
Journal of diabetes science and technology
May 1, 2025
BACKGROUND: Hypoglycemia is common in insulin-treated type 2 diabetes (T2D) patients, which can lead to decreased quality of life or premature death. Deep learning models offer promise of accurate predictions, but data scarcity poses a challenge. Thi...
There is mounting interest in the possibility that metformin, indicated for glycemic control in type 2 diabetes, has a range of additional beneficial effects. Randomized trials have shown that metformin prevents adverse cardiovascular events, and met...
The dose-response relationship between metformin and change in hemoglobin A1c (HbA1c) shows a maximum at 1500-2000 mg/day in patients with type 2 diabetes (T2D) in the U.S. In Japan, there is little evidence on the HbA1c-lowering effect of high-dose ...
Automated insulin delivery (AID) is now integral to the clinical practice of type 1 diabetes (T1D). The objective of this pilot-feasibility study was to introduce a new regulatory and clinical paradigm-a Neural-Net Artificial Pancreas (NAP)-an encod...
In this study, a closed-loop control scheme is proposed for the glucose-insulin regulatory system in type-1 diabetic mellitus (T1DM) patients. Some innovative hybrid glucose-insulin regulators have combined artificial intelligence such as fuzzy logic...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.